We have located links that may give you full text access.
Adverse reactions to gadolinium contrast media: a review of 36 cases.
AJR. American Journal of Roentgenology 1996 October
OBJECTIVE: We investigated the frequency, manifestations, and severity of reactions to gadolinium contrast media in patients who underwent MR imaging at a single institution.
MATERIALS AND METHODS: We reviewed the quality assurance records of 21,000 patients to whom gadolinium contrast media were administered at our institution between January 1990 and October 1994. Of these patients, 36 had adverse reactions. All 36 patients were evaluated by a radiologist at the time of the adverse reaction, and a written report of the findings was completed immediately.
RESULTS: We classified adverse reactions into four groups: mild nonallergic reactions (15 patients with nausea or vomiting), mild reactions resembling allergy (12 patients with hives, diffuse erythema, or skin irritation), moderate reactions resembling allergy (seven patients with respiratory symptoms), and life-threatening reactions resembling allergy (two patients with severe chest tightness, respiratory distress, and periorbital edema). Eleven of these 36 patients who had adverse reactions also had an unusual local reaction of skin discomfort in the extremity through which gadolinium was injected. Four of the 36 patients with adverse reactions had histories of adverse reactions to iodinated contrast media. All four of these patients and one of the remaining 32 patients with adverse reactions required treatment. No patients with adverse reactions died.
CONCLUSION: Although gadolinium contrast media are safe, we found that patients had adverse reactions at a frequency greater than we expected. Severe anaphylactoid reactions occurred in two patients (0.01%). This rate exceeds the rate of 0.0003% reported in the literature. The indexes of suspicion for the occurrence of reactions to gadolinium, and both the documentation and the management of adverse reactions, must be as rigorous for reactions associated with MR imaging contrast agents as they are for reactions associated with iodinated contrast media.
MATERIALS AND METHODS: We reviewed the quality assurance records of 21,000 patients to whom gadolinium contrast media were administered at our institution between January 1990 and October 1994. Of these patients, 36 had adverse reactions. All 36 patients were evaluated by a radiologist at the time of the adverse reaction, and a written report of the findings was completed immediately.
RESULTS: We classified adverse reactions into four groups: mild nonallergic reactions (15 patients with nausea or vomiting), mild reactions resembling allergy (12 patients with hives, diffuse erythema, or skin irritation), moderate reactions resembling allergy (seven patients with respiratory symptoms), and life-threatening reactions resembling allergy (two patients with severe chest tightness, respiratory distress, and periorbital edema). Eleven of these 36 patients who had adverse reactions also had an unusual local reaction of skin discomfort in the extremity through which gadolinium was injected. Four of the 36 patients with adverse reactions had histories of adverse reactions to iodinated contrast media. All four of these patients and one of the remaining 32 patients with adverse reactions required treatment. No patients with adverse reactions died.
CONCLUSION: Although gadolinium contrast media are safe, we found that patients had adverse reactions at a frequency greater than we expected. Severe anaphylactoid reactions occurred in two patients (0.01%). This rate exceeds the rate of 0.0003% reported in the literature. The indexes of suspicion for the occurrence of reactions to gadolinium, and both the documentation and the management of adverse reactions, must be as rigorous for reactions associated with MR imaging contrast agents as they are for reactions associated with iodinated contrast media.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app